Ibrutinib is a Bruton's tyrosine kinase(BTK)inhibitor jointly developed by Pharmacyclics and Janssen Biotech.Ibrutinib is the first small molecule drug targeting BTK for the treatment of sleeve cell lymphoma.This article summarizes the synthesis process of Ibrutinib,in order to provide new ideas for the design of Ibrutinib synthesis routes.
Ibrutinibsynthesis routeBruton's tyrosine kinase(BTK)inhibitorantitumor drug
国家科技期刊平台
NSTL
万方数据
